Evidence map›Paper›PMID 43007554›Full record

ArticleActa neurologica Belgica2026

Association of GLP-1 receptor agonist use with mortality and healthcare utilization in patients with vascular dementia.

Daniel Mandel, Pranjal Rai, Huanwen Chen, Jay Kakadiya, Girish Bathla, Matthew K Mcintyre, Shahrzad Latifi, Brian Connolly, Hamza A Salim, Ahmed Y Azzam and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Daniel Mandel *Department of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, 26505, US. daniel.mandel@wvumedicine.org.
Pranjal Rai *Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Huanwen ChenDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA.
Jay KakadiyaDepartment of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
Girish BathlaDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Matthew K McintyreDepartment of Neurosurgery, Oregon Health and Science University, Portland, OR, USA.
Shahrzad LatifiDepartment of Neuroscience, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
Brian ConnollyDepartment of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
Hamza A SalimDepartment of Neuroradiology, MD Anderson Cancer Center, Houston, TX, USA.
Ahmed Y AzzamDepartment of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, USA.
Muhammed Amir EssibayiDepartment of Neurological Surgery, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, New York, NY, USA.
Vivek S YedavalliDivision of Neuroradiology, Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA.
Majid KhanDivision of Neuroradiology, Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, MD, USA.
Adam A DmytriwNuffield Department of Surgical Sciences, Medical Sciences Division, University of Oxford, Oxford, UK.
David J AltschulDepartment of Neurological Surgery, Montefiore Medical Center, The University Hospital for Albert Einstein College of Medicine, New York, NY, USA.
Marco ColasurdoDepartment of Neurosurgery, Oregon Health and Science University, Portland, OR, USA.
Ajay MalhotraDepartment of Radiology, Yale New Haven hospital, New Haven, CT, USA.
Dheeraj GandhiDepartment of Neurosurgery, University of Maryland Medical Center, Baltimore, MD, USA.
Dhairya A LakhaniDepartment of Neurology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV, 26505, US.

Funding

NIGMS NIH HHS 5U54GM104942-08
6 · The paper itself

Abstract

BACKGROUND AND

objectivesPatients with vascular dementia (VD) have high mortality and frequent acute care use, and no treatment has been shown to improve these outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with a lower incidence of dementia and with cardiovascular benefit in type 2 diabetes, but their association with clinical outcomes in patients with established VD is unknown.

methodsThis retrospective cohort study using a national database identified patients with VD from 2016 to 2025. Patients receiving GLP-1RAs within one month of diagnosis were propensity-score matched with non-users (n = 613 per group). Primary outcome was mortality at 1, 3, and 5 years; secondary outcomes included hospitalizations and emergency visits.

resultsGLP-1RA use was associated with lower risk of mortality at 1 year (8.7% vs. 15.9%; HR 0.49, 95% CI 0.34-0.71), 3 years (23.3% vs. 33.8%; HR 0.58, 95% CI 0.44-0.76), and 5 years (34.4% vs. 54.3%; HR 0.53, 95% CI 0.41-0.69) (all p < 0.001). In addition, GLP-1RA use was associated with lower risk of inpatient admissions and emergency visits.

conclusionGLP-1RA use in patients with VD was associated with lower risk of mortality and healthcare utilization. These beneficial associations warrant prospective randomized trials.

Indexed as

GLP-1RAMortalityTriNetXVascular Dementia

Identifiers

PMID43007554

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.